Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Has anyone received more information about the "private shares" in hospico? I tried get a hold of folks on the phones with answers and it proved to be a pain.
DEAF-TALK, INC. (MGQG)
IMPORTANT NOTICE
MERGER, CANCELATION OF ALL SHARES
To All Shareholders:
The 2014 Annual Meeting of Deaf-Talk, Inc. (the “Company”) was held on Tuesday, October
14th, 2014. At that time, the proposed merger of the Company with and into Hospico, Inc. (the
“Merger”) was approved. The Merger will become effective in the next few days upon the filing
of the proper papers with the State of Georgia.
When the Merger becomes effective, all outstanding shares of Deaf-Talk, Inc. will
automatically be canceled, and the Company’s stock will no longer trade on the OTC
Pink Market.
Please be advised that the Company may not know precisely when trading in the shares of
Deaf-Talk stock may be halted by the OTC as a result of the Merger. Prior to the halt in the
trading of Deaf-Talk stock, it may be possible for you to sell your shares on the market should
you wish to do so. It will not be possible for you to sell your shares in Deaf-Talk after trading
has been halted in those shares.
Shortly after trading in shares of Deaf-Talk’s stock has halted, you will receive instructions from
Hospico, Inc. (the successor to Deaf-Talk as a result of the Merger) as to what to do with your
shares of the former Deaf-Talk. These instructions are important and you should read them
carefully. You must complete the multi-page letter of transmittal (the “Letter”) and the
associated forms (W-2, proof of ownership of shares etc.) After completing the Letter and the
associated forms, you will receive one Hospico share for every one hundred Deaf-Talk shares
that you owned prior to the Merger. You will also receive two cents cash for any amount of
Deaf-Talk shares that are not divisible by hundred, subject to a minimum payment of ten cents.
Hospico shares will not be tradable on the OTC Pink Market.
Please also be advised that if you currently own less than 100 shares of Deaf-Talk, you
will be cashed-out as a result of the Merger and that you may find it easier to sell your
shares on the market at the current market price per share rather than competing the
lengthy forms and disclosures that will be necessary following the Merger which will
result in your receiving two cents per share.
We strongly advise you to get advice from your broker.
Alternatively, you can email us at shareholders@dtinterpreting.com with questions.
Anyone know anything about the new company and how/if it will be traded publicly?
This site looks very good. :)
Great news, yet public support fails :(
I am also interested in learning some things from you. I have been trading pennies for a while and now I am interested in options. Can you e mail at dsnigier@yahoo.com ?
big potential here for big returns
TSTRQ Good evidence for commons to be in tact!!!!! After debt is settle PPS around 1.3 to 1.9$$$$!!!!
IFRS HUGE NEWS!!!
Representatives from Infrared Systems International (OTCBB: IFRS) subsidiary, AquaLiv, Inc., have returned from Kenya with updates concerning their NatuRx(TM) HIV/AIDS treatment.
The company previously announced AquaLiv representatives would be visiting Kenya to make preparations for an upcoming clinical trial of NatuRx(TM) HIV/AIDS. According to the company, while attempting to register the treatment as a drug, Kenyan officials instead recommended filing as an alternative medicine.
"Unlike traditional drugs, all NatuRx(TM) treatments are information-based and do not rely on chemical interaction with active molecules to function," stated AquaLiv CEO, Craig Hoffman. "The Kenyan authorities recognized that our unique treatment has a negligible toxicity and cannot be misused. It is impossible to overdose. In our first regulatory organization experience with NatuRx(TM), the treatment was acknowledged and understood far easier than we anticipated."
Mr. Hoffman continued, "Even more exciting than this warm welcome is the outcome of an approved registration as an alternative medicine. If approved, we will be able to market and sell NatuRx(TM) HIV/AIDS without further clinical trials. And, approval could be granted in the next 30-60 days. The biggest hurdle in biotech is regulatory approval for sale and ongoing costs of continued clinical trials. This will be a big a win for AquaLiv."
In order to produce valuable data, the company intends to continue with the planned clinical trial even though it may not be needed to sell the treatment in Kenya. Several clinics and physicians were identified to participate in the trial. Required protocol is being discussed and budgets are being established for the various participants.
"Kenya is known as the 'Gateway to Africa' because other African nations usually follow suit," added Bill Wright, CEO of Infrared Systems International. "Achieving success in Kenya is generally a successful forecast for all of Africa."
Based on AquaLiv's patented BioT™ Bioinformation Technology, NatuRx™ formulations utilize novel wave-based information composites in lieu of molecules for treatment. The solutions have no contraindications, are non-toxic and resembles common mineral water in analysis.
For more information about AquaLiv, visit their website: http://www.aqualiv.net
About Infrared Systems International:
Infrared Systems International, through its subsidiaries, offers unique solutions and applications for a variety of industries and emerging technologies.
AquaLiv, Inc. is a life sciences research and development company creating novel products for numerous industries. The company's patented technology alters the behavior of organisms, including plants and humans, without chemical interaction. From increased crop yields to drug-free medicine, AquaLiv is providing innovative, ingredient-free solutions to the world's largest problems. To learn more about AquaLiv, please visit: www.aqualiv.net.
Focus Systems, Inc. is a service orientated, desktop virtualization, and VoIP information technology provider. Focus Systems' service essentially eliminates the need for their customers to buy, deploy, and maintain IT infrastructure. The move to cloud computing lowers customers' total cost of ownership by shifting critical systems to Focus -- including servers, backup, software, operating systems, updates, power, cooling, facility space, and internal staffing requirements. For more information, please visit: www.focus-sys.com.
Safe Harbor: Statements contained in this news release, other than those identifying historical facts, constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and the Safe Harbor provisions as contained in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relating to the Company's future expectations, including but not limited to revenues and earnings, technology efficacy, strategies and plans, are subject to safe harbors protection. Actual Company results and performance may be materially different from any future results, performance, strategies, plans, or achievements that may be expressed or implied by any such forward-looking statements. The Company disclaims any obligation to update or revise any forward-looking statements.
IFRS HUGE NEWS!!!
Representatives from Infrared Systems International (OTCBB: IFRS) subsidiary, AquaLiv, Inc., have returned from Kenya with updates concerning their NatuRx(TM) HIV/AIDS treatment.
The company previously announced AquaLiv representatives would be visiting Kenya to make preparations for an upcoming clinical trial of NatuRx(TM) HIV/AIDS. According to the company, while attempting to register the treatment as a drug, Kenyan officials instead recommended filing as an alternative medicine.
"Unlike traditional drugs, all NatuRx(TM) treatments are information-based and do not rely on chemical interaction with active molecules to function," stated AquaLiv CEO, Craig Hoffman. "The Kenyan authorities recognized that our unique treatment has a negligible toxicity and cannot be misused. It is impossible to overdose. In our first regulatory organization experience with NatuRx(TM), the treatment was acknowledged and understood far easier than we anticipated."
Mr. Hoffman continued, "Even more exciting than this warm welcome is the outcome of an approved registration as an alternative medicine. If approved, we will be able to market and sell NatuRx(TM) HIV/AIDS without further clinical trials. And, approval could be granted in the next 30-60 days. The biggest hurdle in biotech is regulatory approval for sale and ongoing costs of continued clinical trials. This will be a big a win for AquaLiv."
In order to produce valuable data, the company intends to continue with the planned clinical trial even though it may not be needed to sell the treatment in Kenya. Several clinics and physicians were identified to participate in the trial. Required protocol is being discussed and budgets are being established for the various participants.
"Kenya is known as the 'Gateway to Africa' because other African nations usually follow suit," added Bill Wright, CEO of Infrared Systems International. "Achieving success in Kenya is generally a successful forecast for all of Africa."
Based on AquaLiv's patented BioT™ Bioinformation Technology, NatuRx™ formulations utilize novel wave-based information composites in lieu of molecules for treatment. The solutions have no contraindications, are non-toxic and resembles common mineral water in analysis.
For more information about AquaLiv, visit their website: http://www.aqualiv.net
About Infrared Systems International:
Infrared Systems International, through its subsidiaries, offers unique solutions and applications for a variety of industries and emerging technologies.
AquaLiv, Inc. is a life sciences research and development company creating novel products for numerous industries. The company's patented technology alters the behavior of organisms, including plants and humans, without chemical interaction. From increased crop yields to drug-free medicine, AquaLiv is providing innovative, ingredient-free solutions to the world's largest problems. To learn more about AquaLiv, please visit: www.aqualiv.net.
Focus Systems, Inc. is a service orientated, desktop virtualization, and VoIP information technology provider. Focus Systems' service essentially eliminates the need for their customers to buy, deploy, and maintain IT infrastructure. The move to cloud computing lowers customers' total cost of ownership by shifting critical systems to Focus -- including servers, backup, software, operating systems, updates, power, cooling, facility space, and internal staffing requirements. For more information, please visit: www.focus-sys.com.
Safe Harbor: Statements contained in this news release, other than those identifying historical facts, constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and the Safe Harbor provisions as contained in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relating to the Company's future expectations, including but not limited to revenues and earnings, technology efficacy, strategies and plans, are subject to safe harbors protection. Actual Company results and performance may be materially different from any future results, performance, strategies, plans, or achievements that may be expressed or implied by any such forward-looking statements. The Company disclaims any obligation to update or revise any forward-looking statements.
IFRS AIDS DRUG NO NEED FOR TRIALS!!
Insane potential here
IFRS HUGE AIDS DRUG NEWS
EXTO !!! Exit Only, Inc./Bayport Corporation Announces 71.6% Reduction of Authorized Shares
EXTO !!! Exit Only, Inc./Bayport Corporation Announces 71.6% Reduction of Authorized Shares
BUYING MORE!
buy buy buy !!!!!
Big run coming!!!
Lets see a filing and watch this run!
MTIZ MERGER LOVE TRIANGLE !!!!!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=65957873
MTIZ HUGGGGGEE MERGER!!!
Hey BD, did anything special happen before GBTR starting moving? I know we are stalling on MCUJ right now, but what can we do?
TCLN insane health care merger
TCLN insane healthcare merger!!
TCLN HUGE MERGER
TCLN MERGER
Techs Loanstar Announces Definitive Merger Agreement With Quture, Inc.
Date : 07/25/2011 @ 8:00AM
Source : MarketWire
Stock : Techs Loanstar, Inc. (TCLN)
Quote : 0.0194 0.0 (0.00%) @ 7:33AM
Techs Loanstar Announces Definitive Merger Agreement With Quture, Inc.
Techs Loanstar (QB) (USOTC:TCLN)
Intraday Stock Chart
Today : Monday 25 July 2011
Techs Loanstar, Inc. (OTCQB: TCLN) (PINKSHEETS: TCLN) today announced that it has signed a Definitive Merger Agreement with Quture Inc. ("Quture"). In the merger, TCLN seeks to acquire a hundred percent interest in Quture to significantly increase shareholder value. The assets of Quture include extensive intellectual property, enhanced software products on the leading technology platform, and clinical content from over 35 years as a leading clinical performance company in the United States. Upon closing, Quture will have accessibility to the capital markets for its financing needs and have currency to achieve dominance as the international standard to measure clinical performance in healthcare consistent with its aggressive growth strategy. Quture seeks to become transparent through public reporting and subject to the requirements for public companies are consistent with that corporate strategy. Closing is subject to customary exchange and approval of schedules and exhibits, audited financial statements, and completing due diligence.
"The acquisition of Quture is an exciting opportunity for the Company and is part of our strategy to increase shareholder value. The implementation of public reporting and policies linking payment to healthcare outcomes has significant implications for the future of healthcare. Our Country faces the challenge of improving healthcare with the understanding that continued growth in healthcare costs is not economically sustainable. Quture's development of a quality performance measurement system positions the Company to transform healthcare by developing the national standard in measuring clinical performance," stated Henry Fong, CEO of Techs Loanstar.
Landon Feazell, Chairman & CEO of Quture, stated: "Merging to become publicly traded and fully reporting is a key corporate strategy. We are committed to the company becoming a dominant player in the private enterprise solutions to improve care and reduce costs of health and healthcare. This merger will strengthen Quture financially while also providing transparency and accountability to the public and to our shareholders. We believe our business proposition and revenue model are sound and that the future of Quture in healthcare performance, outcomes, value, and optimal quality and patient safety are without parallel."
About Quture
Quture, Inc., is a Nevada corporation operating from corporate offices primarily in Florida. Quture's mission is to become the Gold Standard in Healthcare Performance Measurement. Quture provides healthcare organizations, insurers, government payers, and other stakeholders in the healthcare community with performance measurement tools and data sets. Industry experts agree that these performance measures are the "transformative tool" that reduce medical cost and improve quality of care. Quture's management team has 35 years of experience and a long history of working with many of the nation's leading healthcare institutions and insurers as a leader and innovator in measuring clinical performance. Quture plans include developing a revolutionary solution to effectively and efficiently measure clinical performance from multiple vendor databases.
About Techs Loanstar, Inc.
Techs Loanstar, Inc., a Nevada company, was initially organized to provide loan management service and software for the equity and payday loan industry. Upon completion of a Share Exchange Agreement in February 2010, Techs ceased all operations relating to its historical business and adopted the business plan of ZenZuu USA, Inc. ("ZZUSA"). ZZUSA was formed to acquire an exclusive license to use and operate in the United States, an online social database and advertising revenue-share model for the purpose of seeking a business opportunity in the online social network industry.
Forward-Looking Statements
This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. There is no assurance that the finalization of the definitive agreement will be completed.
For Further Information Contact:
Constellation Asset Advisors, Inc.
Jens Dalsgaard
President
+1 (415) 524-8500
TCLN MERGER
Techs Loanstar Announces Definitive Merger Agreement With Quture, Inc.
Date : 07/25/2011 @ 8:00AM
Source : MarketWire
Stock : Techs Loanstar, Inc. (TCLN)
Quote : 0.0194 0.0 (0.00%) @ 7:33AM
Techs Loanstar Announces Definitive Merger Agreement With Quture, Inc.
Techs Loanstar (QB) (USOTC:TCLN)
Intraday Stock Chart
Today : Monday 25 July 2011
Techs Loanstar, Inc. (OTCQB: TCLN) (PINKSHEETS: TCLN) today announced that it has signed a Definitive Merger Agreement with Quture Inc. ("Quture"). In the merger, TCLN seeks to acquire a hundred percent interest in Quture to significantly increase shareholder value. The assets of Quture include extensive intellectual property, enhanced software products on the leading technology platform, and clinical content from over 35 years as a leading clinical performance company in the United States. Upon closing, Quture will have accessibility to the capital markets for its financing needs and have currency to achieve dominance as the international standard to measure clinical performance in healthcare consistent with its aggressive growth strategy. Quture seeks to become transparent through public reporting and subject to the requirements for public companies are consistent with that corporate strategy. Closing is subject to customary exchange and approval of schedules and exhibits, audited financial statements, and completing due diligence.
"The acquisition of Quture is an exciting opportunity for the Company and is part of our strategy to increase shareholder value. The implementation of public reporting and policies linking payment to healthcare outcomes has significant implications for the future of healthcare. Our Country faces the challenge of improving healthcare with the understanding that continued growth in healthcare costs is not economically sustainable. Quture's development of a quality performance measurement system positions the Company to transform healthcare by developing the national standard in measuring clinical performance," stated Henry Fong, CEO of Techs Loanstar.
Landon Feazell, Chairman & CEO of Quture, stated: "Merging to become publicly traded and fully reporting is a key corporate strategy. We are committed to the company becoming a dominant player in the private enterprise solutions to improve care and reduce costs of health and healthcare. This merger will strengthen Quture financially while also providing transparency and accountability to the public and to our shareholders. We believe our business proposition and revenue model are sound and that the future of Quture in healthcare performance, outcomes, value, and optimal quality and patient safety are without parallel."
About Quture
Quture, Inc., is a Nevada corporation operating from corporate offices primarily in Florida. Quture's mission is to become the Gold Standard in Healthcare Performance Measurement. Quture provides healthcare organizations, insurers, government payers, and other stakeholders in the healthcare community with performance measurement tools and data sets. Industry experts agree that these performance measures are the "transformative tool" that reduce medical cost and improve quality of care. Quture's management team has 35 years of experience and a long history of working with many of the nation's leading healthcare institutions and insurers as a leader and innovator in measuring clinical performance. Quture plans include developing a revolutionary solution to effectively and efficiently measure clinical performance from multiple vendor databases.
About Techs Loanstar, Inc.
Techs Loanstar, Inc., a Nevada company, was initially organized to provide loan management service and software for the equity and payday loan industry. Upon completion of a Share Exchange Agreement in February 2010, Techs ceased all operations relating to its historical business and adopted the business plan of ZenZuu USA, Inc. ("ZZUSA"). ZZUSA was formed to acquire an exclusive license to use and operate in the United States, an online social database and advertising revenue-share model for the purpose of seeking a business opportunity in the online social network industry.
Forward-Looking Statements
This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. There is no assurance that the finalization of the definitive agreement will be completed.
For Further Information Contact:
Constellation Asset Advisors, Inc.
Jens Dalsgaard
President
+1 (415) 524-8500
TCLN MERGER
Techs Loanstar Announces Definitive Merger Agreement With Quture, Inc.
Date : 07/25/2011 @ 8:00AM
Source : MarketWire
Stock : Techs Loanstar, Inc. (TCLN)
Quote : 0.0194 0.0 (0.00%) @ 7:33AM
Techs Loanstar Announces Definitive Merger Agreement With Quture, Inc.
Techs Loanstar (QB) (USOTC:TCLN)
Intraday Stock Chart
Today : Monday 25 July 2011
Techs Loanstar, Inc. (OTCQB: TCLN) (PINKSHEETS: TCLN) today announced that it has signed a Definitive Merger Agreement with Quture Inc. ("Quture"). In the merger, TCLN seeks to acquire a hundred percent interest in Quture to significantly increase shareholder value. The assets of Quture include extensive intellectual property, enhanced software products on the leading technology platform, and clinical content from over 35 years as a leading clinical performance company in the United States. Upon closing, Quture will have accessibility to the capital markets for its financing needs and have currency to achieve dominance as the international standard to measure clinical performance in healthcare consistent with its aggressive growth strategy. Quture seeks to become transparent through public reporting and subject to the requirements for public companies are consistent with that corporate strategy. Closing is subject to customary exchange and approval of schedules and exhibits, audited financial statements, and completing due diligence.
"The acquisition of Quture is an exciting opportunity for the Company and is part of our strategy to increase shareholder value. The implementation of public reporting and policies linking payment to healthcare outcomes has significant implications for the future of healthcare. Our Country faces the challenge of improving healthcare with the understanding that continued growth in healthcare costs is not economically sustainable. Quture's development of a quality performance measurement system positions the Company to transform healthcare by developing the national standard in measuring clinical performance," stated Henry Fong, CEO of Techs Loanstar.
Landon Feazell, Chairman & CEO of Quture, stated: "Merging to become publicly traded and fully reporting is a key corporate strategy. We are committed to the company becoming a dominant player in the private enterprise solutions to improve care and reduce costs of health and healthcare. This merger will strengthen Quture financially while also providing transparency and accountability to the public and to our shareholders. We believe our business proposition and revenue model are sound and that the future of Quture in healthcare performance, outcomes, value, and optimal quality and patient safety are without parallel."
About Quture
Quture, Inc., is a Nevada corporation operating from corporate offices primarily in Florida. Quture's mission is to become the Gold Standard in Healthcare Performance Measurement. Quture provides healthcare organizations, insurers, government payers, and other stakeholders in the healthcare community with performance measurement tools and data sets. Industry experts agree that these performance measures are the "transformative tool" that reduce medical cost and improve quality of care. Quture's management team has 35 years of experience and a long history of working with many of the nation's leading healthcare institutions and insurers as a leader and innovator in measuring clinical performance. Quture plans include developing a revolutionary solution to effectively and efficiently measure clinical performance from multiple vendor databases.
About Techs Loanstar, Inc.
Techs Loanstar, Inc., a Nevada company, was initially organized to provide loan management service and software for the equity and payday loan industry. Upon completion of a Share Exchange Agreement in February 2010, Techs ceased all operations relating to its historical business and adopted the business plan of ZenZuu USA, Inc. ("ZZUSA"). ZZUSA was formed to acquire an exclusive license to use and operate in the United States, an online social database and advertising revenue-share model for the purpose of seeking a business opportunity in the online social network industry.
Forward-Looking Statements
This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. There is no assurance that the finalization of the definitive agreement will be completed.
For Further Information Contact:
Constellation Asset Advisors, Inc.
Jens Dalsgaard
President
+1 (415) 524-8500
next big stock is MCUJ... Volume very slow today much like GBTR was for days before it ran. I was pounding the table on that stock and it didnt run until days later. PPS went from .02 to .61 in a matter of a week after the run began.
FWIW the O/S is the same now as it was back when it was $2. (Unlike 99.9% other stocks that drop in a similar manner)
MCUJ is one people wanna watch to accumulate. Read over this link and info. MCUJ was a $2 AMEX stock a few years back.. Stock plummeted after announcing negative results from its pivotal phase 3 trial of MC-1. O/S hasnt changed in all this time.. From there they ran into debt issues. On 7/18 they announced via PR they resolved $32M in debt they had. CEO said that was an issue that plagued them. Now with debt gone they can move forward with clinical trials that were on hold. This is the rebirth of MCUJ.
investorshub.advfn.com/boards/read_msg.aspx?message_id=65353658
finman1107/19/2011 12:02:46 PM | | 116 reads | Post #29986935
Want to know why this is flying?
The company is no longer faced with the possibiity of being taken over by its debtholders.
The company can continue its development of other drugs ... like Tardoxal which has no financing partner; announcing a financing partner could be the next big thing for the company.
It's hard to know what the company is worth right now.
Take a look at a chart that goes into 2007 ....
This thing used to trade around $1 with 120 Million Shares Outstanding.
Today we have 190 Million Shares (this includes the recent options).
With the company avoiding receivership, its obvious we are undervalued.
Maybe a $1 should not be expected by the end of the week, but I wonder what will be a decent price
.10?
.25? Maybe higher?
Watch as the news hits more traders.
A company that has a drug at market .... old debt problem resolved ... new drug that is in Phase 2 for a market with a value of 150 to 600 Million per year?
Old debt problem resolved .... new product that is in Phase 2 Trials ...... two additional drugs that have had development halted due to possible receivership.
I am loving this attempt to keep it canned at
.055 ..... Obviously someone is trying to get old traders to bail out. [color=red][/color]
I am in and trying to spread the word around IHUB
MCUJ incredible Pharma stock next big stock is MCUJ... Volume very slow today much like GBTR was for days before it ran. PPS went from .02 to .61 in a matter of a week after the run began.
FWIW the O/S is the same now as it was back when it was $2. (Unlike 99.9% other stocks that drop in a similar manner)
MCUJ is one people wanna watch to accumulate. Read over this link and info. MCUJ was a $2 AMEX stock a few years back.. Stock plummeted after announcing negative results from its pivotal phase 3 trial of MC-1. O/S hasnt changed in all this time.. From there they ran into debt issues. On 7/18 they announced via PR they resolved $32M in debt they had. CEO said that was an issue that plagued them. Now with debt gone they can move forward with clinical trials that were on hold. This is the rebirth of MCUJ.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=65353658
finman1107/19/2011 12:02:46 PM | | 116 reads | Post #29986935
Want to know why this is flying?
The company is no longer faced with the possibiity of being taken over by its debtholders.
The company can continue its development of other drugs ... like Tardoxal which has no financing partner; announcing a financing partner could be the next big thing for the company.
It's hard to know what the company is worth right now.
Take a look at a chart that goes into 2007 ....
This thing used to trade around $1 with 120 Million Shares Outstanding.
Today we have 190 Million Shares (this includes the recent options).
With the company avoiding receivership, its obvious we are undervalued.
Maybe a $1 should not be expected by the end of the week, but I wonder what will be a decent price
.10?
.25? Maybe higher?
Watch as the news hits more traders.
A company that has a drug at market .... old debt problem resolved ... new drug that is in Phase 2 for a market with a value of 150 to 600 Million per year?
Old debt problem resolved .... new product that is in Phase 2 Trials ...... two additional drugs that have had development halted due to possible receivership.
I am loving this attempt to keep it canned at
.055 ..... Obviously someone is trying to get old traders to bail out.
next big stock is MCUJ... Volume very slow today much like GBTR was for days before it ran. I was pounding the table on that stock and it didnt run until days later. PPS went from .02 to .61 in a matter of a week after the run began.
FWIW the O/S is the same now as it was back when it was $2. (Unlike 99.9% other stocks that drop in a similar manner)
MCUJ is one people wanna watch to accumulate. Read over this link and info. MCUJ was a $2 AMEX stock a few years back.. Stock plummeted after announcing negative results from its pivotal phase 3 trial of MC-1. O/S hasnt changed in all this time.. From there they ran into debt issues. On 7/18 they announced via PR they resolved $32M in debt they had. CEO said that was an issue that plagued them. Now with debt gone they can move forward with clinical trials that were on hold. This is the rebirth of MCUJ.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=65353658
finman1107/19/2011 12:02:46 PM | | 116 reads | Post #29986935
Want to know why this is flying?
The company is no longer faced with the possibiity of being taken over by its debtholders.
The company can continue its development of other drugs ... like Tardoxal which has no financing partner; announcing a financing partner could be the next big thing for the company.
It's hard to know what the company is worth right now.
Take a look at a chart that goes into 2007 ....
This thing used to trade around $1 with 120 Million Shares Outstanding.
Today we have 190 Million Shares (this includes the recent options).
With the company avoiding receivership, its obvious we are undervalued.
Maybe a $1 should not be expected by the end of the week, but I wonder what will be a decent price
.10?
.25? Maybe higher?
Watch as the news hits more traders.
A company that has a drug at market .... old debt problem resolved ... new drug that is in Phase 2 for a market with a value of 150 to 600 Million per year?
Old debt problem resolved .... new product that is in Phase 2 Trials ...... two additional drugs that have had development halted due to possible receivership.
I am loving this attempt to keep it canned at
.055 ..... Obviously someone is trying to get old traders to bail out.
next big stock is MCUJ... Volume very slow today much like GBTR was for days before it ran. I was pounding the table on that stock and it didnt run until days later. PPS went from .02 to .61 in a matter of a week after the run began.
FWIW the O/S is the same now as it was back when it was $2. (Unlike 99.9% other stocks that drop in a similar manner)
MCUJ is one people wanna watch to accumulate. Read over this link and info. MCUJ was a $2 AMEX stock a few years back.. Stock plummeted after announcing negative results from its pivotal phase 3 trial of MC-1. O/S hasnt changed in all this time.. From there they ran into debt issues. On 7/18 they announced via PR they resolved $32M in debt they had. CEO said that was an issue that plagued them. Now with debt gone they can move forward with clinical trials that were on hold. This is the rebirth of MCUJ.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=65353658
finman1107/19/2011 12:02:46 PM | | 116 reads | Post #29986935
Want to know why this is flying?
The company is no longer faced with the possibiity of being taken over by its debtholders.
The company can continue its development of other drugs ... like Tardoxal which has no financing partner; announcing a financing partner could be the next big thing for the company.
It's hard to know what the company is worth right now.
Take a look at a chart that goes into 2007 ....
This thing used to trade around $1 with 120 Million Shares Outstanding.
Today we have 190 Million Shares (this includes the recent options).
With the company avoiding receivership, its obvious we are undervalued.
Maybe a $1 should not be expected by the end of the week, but I wonder what will be a decent price
.10?
.25? Maybe higher?
Watch as the news hits more traders.
A company that has a drug at market .... old debt problem resolved ... new drug that is in Phase 2 for a market with a value of 150 to 600 Million per year?
Old debt problem resolved .... new product that is in Phase 2 Trials ...... two additional drugs that have had development halted due to possible receivership.
I am loving this attempt to keep it canned at
.055 ..... Obviously someone is trying to get old traders to bail out.
TSTRQ - if commons survive, we hit big? If not, :(
(TDLPQ) Commons survive
Commons Survive!: Screenshot and link to the PACER where the CFO states there will be a 'distribution to equity'.
That means commons survive: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64924417
And the document here explains on pg 3/4 how this will happen in tranches: http://www.scribd.com/doc/59606881/Transdel-Points-and-Authorities-pertaining-to-Asset-Sale
--
Please do your DD. PACER filing links and DD have already been provided here
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64993347
and here
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=65016518
Voila.
And the other Q stock is different from this one. Apples and Oranges.
Here commons survive for sure.
lets see some volume during power hour
TDLPQ commons survive!
Commons Survive!: Screenshot and link to the PACER where the CFO states there will be a 'distribution to equity'.
That means commons survive: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64924417
And the document here explains on pg 3/4 how this will happen in tranches: http://www.scribd.com/doc/59606881/Transdel-Points-and-Authorities-pertaining-to-Asset-Sale
TDLPQ
Please do your DD. PACER filing links and DD have already been provided here
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64993347
and here
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=65016518
Voila.
And the other Q stock is different from this one. Apples and Oranges.
Here commons survive for sure.
if that happens I'm gonna fly to you and buy you dinner :)
TDLPQ COMMONS SURVIVE!!!!
Commons Survive!: Screenshot and link to the PACER where the CFO states there will be a 'distribution to equity'.
That means commons survive: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64924417
And the document here explains on pg 3/4 how this will happen in tranches: http://www.scribd.com/doc/59606881/Transdel-Points-and-Authorities-pertaining-to-Asset-Sale
--
Please do your DD. PACER filing links and DD have already been provided here
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64993347
and here
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=65016518
Voila.
And the other Q stock is different from this one. Apples and Oranges.
Here commons survive for sure.
TDLPQ Commons Survive!
Commons Survive!: Screenshot and link to the PACER where the CFO states there will be a 'distribution to equity'.
That means commons survive: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64924417
And the document here explains on pg 3/4 how this will happen in tranches: http://www.scribd.com/doc/59606881/Transdel-Points-and-Authorities-pertaining-to-Asset-Sale
--
Please do your DD. PACER filing links and DD have already been provided here
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=64993347
and here
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=65016518
Voila.
And the other Q stock is different from this one. Apples and Oranges.
Here commons survive for sure.